Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:alsoKnownAs |
Uhambo trial
|
| gptkbp:basedOn |
RV144 trial
|
| gptkbp:endDate |
2020
|
| gptkbp:enrollment |
over 5,400 participants
|
| https://www.w3.org/2000/01/rdf-schema#label |
HVTN 702
|
| gptkbp:location |
gptkb:South_Africa
|
| gptkbp:period |
Phase 2b/3
|
| gptkbp:reasonForStopping |
vaccine did not prevent HIV infection
|
| gptkbp:sponsor |
gptkb:National_Institute_of_Allergy_and_Infectious_Diseases
gptkb:HIV_Vaccine_Trials_Network |
| gptkbp:startDate |
2016
|
| gptkbp:status |
stopped early
|
| gptkbp:studiedBy |
HIV vaccine
|
| gptkbp:targetAudience |
HIV-negative adults
|
| gptkbp:vaccineRegimen |
ALVAC-HIV and bivalent gp120 protein
|
| gptkbp:bfsParent |
gptkb:HIV_Vaccine_Trials_Network
|
| gptkbp:bfsLayer |
7
|